|
Colorectal Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In vitro experiments indicated that miR-144 decreased NRAS expression in different CRC cell lines (SW480, LoVo, and Caco2).
|
31693229 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathologic features and frequency of KRAS mutations in colorectal cancer (CRC) patients have been reported; however, the characteristics and impact of NRAS and HRAS mutations on the survival of CRC patients have seldom been addressed.
|
27394063 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mutations of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status have become an important part of the assessment of patients with colorectal cancer (CRC), while respective clinicopathologic features and prognostic significance in specific stages and related detection strategies remain unclear.
|
31162857 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
NRAS-mutation(+) CRC preferentially occurred in elder patients (P = 0.02) and at the distal colon (P = 0.006), showed significantly less lymph vessel invasion (P = 0.002), and correlated with LME (P = 8 × 10<sup>-5</sup> ).
|
28378457 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In advanced colorectal carcinoma (CRC) patients, extended RAS mutations testing (KRAS exons 2 to 4 and NRAS exons 2 to 4) is a prerequisite for patient stratification to anti-EGFr therapy.
|
26163758 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although the presence of HER2 amplifications and oncogenic mutations in KRAS, NRAS, and BRAF are associated with EGFR-targeted therapy resistance, for a large population of CRC patients the underlying mechanism of RAS-MEK-ERK hyperactivation is not clear.
|
30858928 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two-hundred and forty-two formalin-fixed paraffin-embedded (FFPE) human malignant colorectal cancer (CRC) tissue samples were identified in departmental archives and tested with both the Idylla NRAS-BRAF mutation test and the Agena Bioscience MassARRAY test.
|
28899979 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Herein, we demonstrate that the presence of an oncogenic KRAS allele results in elevated levels of GTP-bound N-RAS (N-RAS.GTP) in two human colorectal cancer cell lines, HCT 116 and DLD-1, compared to their isogenic counterparts in which the mutant KRAS allele has been disrupted by homologous recombination.
|
17130841 |
2007 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor.
|
26824184 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that colorectal carcinomas with either K-ras mutations or altered forms of N-ras protein may increase their tumorigenic potential via the induction of cathepsin L or B expression levels.
|
9699522 |
1998 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations occur in 3-5% of colorectal cancer.
|
24806288 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the multivariate setting, left-sided CRC only turned out as a significant positive prognostic parameter regarding progression-free survival, irrespective of the type of chemotherapy or BRAF and NRAS mutations.
|
30711966 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
|
21305640 |
2011 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
As a group, CRC complicating Crohn's colitis is BRAF (97 %) and NRAS (100 %) wild type and the vast majority is microsatellite stable (94 %); KRAS-mutations were found in six cases (18 %).
|
27026089 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
|
28560458 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The clinically relevant genetic aberrations described in this review include mutation analyses of RAS (KRAS and NRAS), BRAF and PI3K in colorectal cancer, KIT or PDGFR alpha as well as BRAF, NRAS and KIT in malignant melanoma.
|
26358176 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activating oncogenic mutations in KRAS and NRAS are common in CRC, driving tumor progression and influencing efficacy of both cytotoxic and targeted therapies.
|
31427573 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
RAS (KRAS and NRAS) testing is required to predict anti-epidermal growth factor receptor (EGFR) treatment efficacy in metastatic colorectal cancer (CRC).
|
26137573 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A subset of patients with metastatic CRC (n = 44) wild-type for KRAS, NRAS, and BRAF who received anti-epidermal growth factor receptor therapy with mutated SMAD4 (n = 13) had shorter progression-free survival duration than did patients wild-type for SMAD4 (n = 31) (median, 111 days versus 180 days; p = 0.003 [log-rank test]).
|
28267766 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
According to current clinical guidelines mutational analysis for KRAS and NRAS is recommended prior to EGFR-directed therapy of colorectal cancer (CRC) in the metastatic setting.
|
26220423 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Approximately 2-6% of colorectal cancers harbor NRAS mutations.
|
23400451 |
2013 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
MI is not likely to be involved in the same underlying defect that generates rare HRAS1 alleles in colorectal carcinoma.
|
11724366 |
2001 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We did, however, identify a KRAS A146 mutation in the ML-2 acute myeloid leukemia cell line and an NRAS A146 mutation in the NALM-6 B-cell acute lymphoblastic leukemia line, suggesting that the contribution of codon 146 mutations is not entirely restricted to colorectal cancers or to KRAS.
|
16969076 |
2006 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We also carried out a meta-analysis of this study and 22 other published studies, estimating the relative risk of cancer (such as bladder, breast, or colorectal cancer) when one of the rare HRAS1 alleles was present.
|
8336750 |
1993 |